Inovio Pharmaceuticals suspended its at-the-market equity offering program, halting future share sales until a new prospectus is filed, while the existing sales agreement remains in effect.
Key takeaways
The company suspended and terminated its ATM offering prospectus, preventing new share sales under the existing program.
No future common stock sales will occur through this ATM program until a new prospectus is filed with the SEC.
The sales agreement with Oppenheimer & Co. remains fully operational despite the prospectus suspension.
The company previously sold 1,319,644 shares through this program, generating $3.2 million in gross proceeds.
The ATM program was established through a sales agreement dated August 13, 2024.